Personal information

Emails & domains

Verified email domains

Activities

Collapse all

Education and qualifications (1)

University of Oxford: Oxford, Oxfordshire, GB

(Medical Sciences Doctoral Training Centre; St Anne's College)
Education
Source: check_circle
ORCID Integration at the University of Oxford

Works (27)

UK cancer vaccine advance – Recognising and realising opportunities

Cambridge Prisms: Precision Medicine
2025 | Journal article
DOI: 10.1017/pcm.2024.5
Part of ISSN: 2752-6143
Contributors: Charles Craddock; Philip Earwaker; Matthew Fittall; Elisa Fontana; Divya Ganesh; Marco Gerlinger; Qamar Ghafoor; Robert P Jones; Victoria Kunene; Lennard Lee et al.
Source: Self-asserted source
Martin Little

Safe prescribing in cancer patients during the COVID-19 pandemic and outcomes following restart of cancer care following SARS-CoV-2infection: The COV-SPOT initiative

International Journal of Cancer
2025-03-10 | Journal article
DOI: 10.1002/ijc.35377
Part of ISSN: 0020-7136
Part of ISSN: 1097-0215
Contributors: Nathan Appanna; Rosie Mew; Sophie Williams; Thomas Starkey; Grisma Patel; Laura Hudson; Emma Burke; Francesca Aquilina; Caroline Harnett; Harrison Boult et al.
Source: Self-asserted source
Martin Little

16P Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity

Immuno-Oncology and Technology
2024-12 | Journal article
DOI: 10.1016/j.iotech.2024.100899
Part of ISSN: 2590-0188
Contributors: M. Little; G. Milotay; S. Mackay; D. Muldoon; A-A. Oluwafemi; R. Watson; O. Tong; S. Sun; C. Taylor; M. Payne et al.
Source: Self-asserted source
Martin Little

Defining the genetic determinants of CD8+T cell receptor repertoire in the context of immune checkpoint blockade

2024-11-06 | Preprint
DOI: 10.1101/2024.11.04.618564
Contributors: Esther S. Ng; Orion Tong; Chelsea Taylor; Robert Watson; Bo Sun; Gusztav Milotay; Sophie MacKay; James J Gilchrist; Martin Little; Benjamin P Fairfax et al.
Source: check_circle
Crossref

Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy

2024-10-09 | Preprint
DOI: 10.1101/2024.10.09.24315144
Contributors: Gusztav Milotay; Martin Little; Robert Watson; Dylan Muldoon; Orion Tong; Chelsea Taylor; Sophie MacKay; Isar Nassiri; Bo Sun; Louisa M Webb et al.
Source: check_circle
Crossref

Scientific Business Abstracts

QJM: An International Journal of Medicine
2024-09-19 | Journal article
DOI: 10.1093/qjmed/hcae157
Part of ISSN: 1460-2725
Part of ISSN: 1460-2393
Contributors: Faye Cooles; Gemma Vidal-Pedrola; Najib Naamane; Arthur Pratt; Ben Barron-Millar; Amy Anderson; Catharien Hilkens; John Casement; Vincent Bondet; Darragh Duffy et al.
Source: Self-asserted source
Martin Little

Peripheral monocyte transcriptomics associated with immune checkpoint blockade outcomes in metastatic melanoma

2024-01-25 | Preprint
DOI: 10.1101/2024.01.25.24301653
Contributors: Rosalin A Cooper; Chelsea A Taylor; Robert A Watson; Orion Tong; Isar Nassiri; Piyush Kumar Sharma; Martin Little; Weiyu Ye; Surya Koturan; Sara Danielli et al.
Source: check_circle
Crossref

135P The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB)

Annals of Oncology
2023-10 | Journal article
DOI: 10.1016/j.annonc.2023.09.2860
Part of ISSN: 0923-7534
Contributors: R.A. Watson; O. Tong; C. Taylor; G. Vallance; F. Matos Santo; M. Little; B. Sun; B. Shine; M.R. Middleton; N.A. Coupe et al.
Source: Self-asserted source
Martin Little

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

Scientific Reports
2023-07-25 | Journal article
DOI: 10.1038/s41598-023-36990-9
Part of ISSN: 2045-2322
Contributors: Thomas Starkey; Maria C. Ionescu; Michael Tilby; Martin Little; Emma Burke; Matthew W. Fittall; Sam Khan; Justin K. H. Liu; James R. Platt; Rosie Mew et al.
Source: Self-asserted source
Martin Little

The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research

British Journal of Cancer
2023-06-15 | Journal article
DOI: 10.1038/s41416-023-02251-9
Part of ISSN: 0007-0920
Part of ISSN: 1532-1827
Contributors: Matthew Fittall; Justin Liu; James Platt; Maria Ionescu; Remarez Sheehan; Sukhmunni Johal; Rosie Mew; James Clark; Izzy Watts; Arvind Tripathy et al.
Source: Self-asserted source
Martin Little

Abstract 804: The temporal evolution in disease phenotype of COVID-19 hospitalisation, intensive care and case fatality rates in cancer patients across the United Kingdom (UKCCP)

Cancer Research
2023-04-04 | Journal article
DOI: 10.1158/1538-7445.am2023-804
Part of ISSN: 1538-7445
Contributors: Thomas Starkey; Maria C. Ionescu; Matthew W. Fittall; Michael Tilby; Alex Burnett; Rosie Hattersley; Sam Khan; Martin Little; Justin K. Liu; James R. Platt et al.
Source: Self-asserted source
Martin Little

Supplementary Table from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488993.v1
Contributors: Susana Banerjee; Vasiliki Michalarea; Joo Ern Ang; Alvaro Ingles Garces; Andrea Biondo; Ionut-Gabriel Funingana; Martin Little; Ruth Ruddle; Florence Raynaud; Ruth Riisnaes et al.
Source: check_circle
Crossref
grade
Preferred source (of 22)‎

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer

JAMA Oncology
2022-12-22 | Journal article
DOI: 10.1001/jamaoncol.2022.5974
Part of ISSN: 2374-2437
Contributors: Lennard Y. W. Lee; Michael Tilby; Thomas Starkey; Maria C. Ionescu; Alex Burnett; Rosie Hattersley; Sam Khan; Martin Little; Justin K. H. Liu; James R. Platt et al.
Source: Self-asserted source
Martin Little

Safe prescribing in cancer patients during the COVID‐19 pandemic: A new initiative from the UK Cancer Coronavirus Project (UKCCP) team

International Journal of Cancer
2022-12-08 | Journal article
DOI: 10.1002/ijc.34387
Part of ISSN: 0020-7136
Part of ISSN: 1097-0215
Contributors: Nathan Appanna; Grisma Patel; Emma Burke; Alexander Burnett; James Clark; Rosie Mew; Sam Khan; Martin Little; Justin Liu; Hari Panneerselvam et al.
Source: Self-asserted source
Martin Little

A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

Clinical Cancer Research
2022-11-01 | Journal article
DOI: 10.1158/1078-0432.CCR-22-1268
Contributors: Susana Banerjee; Vasiliki Michalarea; Joo Ern Ang; Alvaro Ingles Garces; Andrea Biondo; Ionut-Gabriel Funingana; Martin Little; Ruth Ruddle; Florence Raynaud; Ruth Riisnaes et al.
Source: check_circle
Crossref

EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients

ESMO Open
2022-10 | Journal article
DOI: 10.1016/j.esmoop.2022.100550
Part of ISSN: 2059-7029
Contributors: Martin Little
Source: Self-asserted source
Martin Little
grade
Preferred source (of 2)‎

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study

European journal of cancer (Oxford, England : 1990)
2022-07 | Journal article
PMC: PMC9276646
Contributors: Lee L; Ionescu M; Starkey T; Little M; Tilby M; Tripathy A; Mckenzie H; Al-Hajji Y; Appanna N; Barnard M et al.
Source: Self-asserted source
Martin Little via Europe PubMed Central
grade
Preferred source (of 3)‎

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.

The Lancet. Oncology
2022-05 | Journal article
DOI: 10.1016/s1470-2045(22)00202-9
PMID: 35617989
PMC: PMC9126559
Contributors: Lee LYW; Starkey T; Ionescu MC; Little M; Tilby M; Tripathy AR; Mckenzie HS; Al-Hajji Y; Barnard M; Benny L et al.
Source: Self-asserted source
Martin Little via Europe PubMed Central

Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

Exploration of Targeted Anti-tumor Therapy
2022-04-24 | Journal article
DOI: 10.37349/etat.2022.00078
Contributors: Aglaia Skolariki; Jamie D’Costa; Martin Little; Simon Lord
Source: check_circle
Crossref

As COVID-19 cases surge despite mass vaccination, it's time to focus on the vulnerable.

Ecancermedicalscience
2021-11 | Journal article
DOI: 10.3332/ecancer.2021.ed117
PMID: 35047077
PMC: PMC8723744
Contributors: Little M; Fittall M; McKenzie H; Tilby M; Tripathy A; Lee LY
Source: Self-asserted source
Martin Little via Europe PubMed Central

1493P An evaluation of the psychological impact of early phase clinical trials in cancer patients

Annals of Oncology
2021-09 | Conference abstract
DOI: 10.1016/j.annonc.2021.08.821
Part of ISSN: 0923-7534
Source: Self-asserted source
Martin Little

725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Annals of Oncology
2021-09 | Conference abstract
DOI: 10.1016/j.annonc.2021.08.1168
Part of ISSN: 0923-7534
Source: Self-asserted source
Martin Little

Enrolment of older adults with cancer in early phase clinical trials-an observational study on the experience in the north west of England.

Age and ageing
2021-09 | Journal article
DOI: 10.1093/ageing/afab091
PMID: 34107012
Contributors: Gomes F; Descamps T; Lowe J; Little M; Lauste R; Krebs MG; Graham D; Thistlethwaite F; Carter L; Cook N
Source: Self-asserted source
Martin Little via Europe PubMed Central

Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Cancer Research
2021-07-01 | Conference paper
DOI: 10.1158/1538-7445.am2021-ct019
Part of ISSN: 0008-5472
Part of ISSN: 1538-7445
Source: Self-asserted source
Martin Little

Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in<i>KRAS</i>mutant cancers

Tumor Biology
2020-08-15 | Conference poster
DOI: 10.1158/1538-7445.am2020-ct143
Source: Self-asserted source
Martin Little

A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.

Journal of Clinical Oncology
2020-05-20 | Journal article
DOI: 10.1200/jco.2020.38.15_suppl.6043
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Source: Self-asserted source
Martin Little

Emphysematous cholecystitis in a patient with metastatic pancreatic neuroendocrine tumour.

QJM : monthly journal of the Association of Physicians
2017-04 | Journal article
DOI: 10.1093/qjmed/hcx012
PMID: 28062742
Contributors: Khan M; Little M; Campbell G; Laasch HU; Cooksley T
Source: Self-asserted source
Martin Little via Europe PubMed Central
How many people are using ORCID?